Skip to main content

Table 1 Participant & family demographic and clinical characteristics at recruitment

From: FAB: First UK feasibility trial of a future randomised controlled trial of Family focused treatment for Adolescents with Bipolar disorder

  Immediate arm, n = 14 Delayed arm, n = 13 Total, n = 27
Age in years: mean (sd) 16.2 (1.3) 16.1 (1.5) 16.1 (1.4)
Index of Multiple Deprivation: mean (sd) 23.4 (14.8) 23.2 (11.1) 23.3 (12.9)
CGAS rating: mean (sd)
 Current (last 2 weeks) 84 (7) 81.4 (5.2) 82.7 (6.3)
 Most severe past episode 25.1 (5) 22.4 (8.1) 23.8 (6.8)
 Highest in prior year 81 (7) 81.5 (5) 81.2 (7)
Gender: n (%)
 Female 13 (92.9) 10 (76.9) 23 (85.2)
Ethnicity: n (%)
 White British 13 (92.9) 12 (92.3) 25 (92.6)
 White other 0 (0) 1 (7.7) 1 (3.7)
 Mixed 1 (7.1) 0 (0) 1 (3.7)
Type of bipolar disorder: n (%)
 Bipolar I 8 (57.1) 7 (53.8) 15 (55.6)
 Bipolar II 6 (42.9) 5 (38.5) 11 (40.7)
 Bipolar NOS 0 (0) 1 (7.7) 1 (3.7)
Comorbid disorders
 GAD 0 (0) 2 (15.4) 2 (7.4)
 ASD 2 (14.3) 2 (15.4) 4 (14.8)
 ADHD 1 (7.1) 0 (0) 1 (3.7)
 ASD + ADHD 1 (7.1) 0 (0) 1 (3.7)
 Substance abuse or dependence disorder (past 3 months) 0 (0) 0 (0) 0 (0)
Mood episodes
 Age of diagnosis of BD in years mean (sd) 12.8 (1.6) 12.9 (1.3) 12.8 (1.4)
Hypomania
 Number of participants n (%) 8 (57.1) 8 (61.5) 16 (59.3)
 Number of episodes mean (sd) 3 (1.1) 2.9 (2) 3 (1)
 Lifetime duration in weeks mean (sd) 7.8 (4.4) 8.6 (4.5) 8.1 (4.3)
 Admissions to hospital 0 (0) 0 (0) 0 (0)
Mania
 Number of participants n (%) 8 (57.1) 7 (53.8) 15 (55.6)
 Number of episodes mean (sd) 2.9 (0.8) 2.7 (0.8) 2.8 (0.8)
 Lifetime duration in weeks mean (sd) 13.4 (5.2) 14 (5.3) 13.7 (5.1)
 Number of participants experiencing psychotic episodes n (%) 5 (35.7) 4 (30.1) 9 (33.3)
 Admissions to hospital n (%) 4 (30.1) 3 (23.1) 7 (25.9)
Depression
 Number of participants n (%) 14 (100) 13 (100) 27 (100)
 Number of episodes mean (sd) 4.2 (1.1) 4.2 (1.1) 4.2 (1.1)
 Lifetime duration in weeks mean (sd) 37.2 (16.9) 35.9 (16.2) 36.6 (16.5)
 Number of participants experiencing psychotic episodes n (%) 10 (71.4) 9 (69.2) 19 (70.4)
 Admissions to hospital n (%) 7 (50) 6 (46.2) 13 (48.1)
Medication treatments at trial entry
 Mood stabilizer 5 (35.7) 5 (38.5) 10 (37)
 Antipsychotic 8 (57.1) 10 (76.9) 18 (66.7)
 Other 1 (7.1) 0 (0) 1 (3.7)
 None 4 (28.6) 0 (0) 4 (14.8)
Family medical history (first degree relatives)
 Bipolar disorder 5 (35.7) 4 (30.8) 9 (33.3)
 Depression 4 (28.6) 10 (76.9) 14 (51.9)
 Anxiety 2 (14.3) 1 (7.7) 3 (11.1)
 ADHD 2 (14.3) 3 (23.1) 5 (18.5)
 ASD 2 (14.3) 2 (15.4) 4 (14.8)
 Physical illness 1 (7.1) 0 (0) 1 (3.7)
 Other 2 (14.3) 3 (23.1) 5 (18.5)
  1. CGAS Children’s Global Assessment Scale, NOS not otherwise specified, GAD generalised anxiety disorder, ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder